Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAMBOO: Abicipar Pegol in Japanese Patients with Neovascular AMD
NCT02181517Phase 2Completed
- Sponsor
- Allergan
- Start
- Jul 2014
- Primary completion
- Mar 2015
- Modality
- Carrier/Scaffold Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of abicipar pegol in neovascular age-related macular degeneration (NVAMD), sponsored by Allergan. Started Jul 2014; status: completed.
02
Drugs
abicipar pegol
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02181517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181517.